SPARC into Bio modifying for antibody drugs Business

SPARC enters into a licensing agreement with Biomodifying for antibody drugs 

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced that it has entered into an agreement with Biomodifying LLC to exclusively license Biomodifying’s intellectual property, including all patents and patent applications owned or controlled by Biomodifying, along with antibodies developed for multiple uses including for cancer. Under the agreement, Biomodifying is eligible for an upfront payment, milestone payments on pre-specifi ed clinical, regulatory, and commercial milestones, as well as royalties on sales. In addition, SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP. “This is an important milestone for SPARC. 

The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPARC into a company focussed on novel treatment modalities, including bi-specifi c antibodies and antibody drug conjugates,” said Mr. Anil Raghavan, CEO, SPARC.